FLORA DIAMREYAN: Open Payments
NPI 1477626521 · RANCHO CUCAMONGA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,748 in 121 payments from 14 companies in 2025. Trend: 2023 $1,999 · 2024 $2,067 · 2025 $2,748
Food & beverage: $2,748
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $576 |
| ABBVIE INC. | 24 | $411 |
| Axsome Therapeutics, Inc. | 11 | $285 |
| Janssen Pharmaceuticals, Inc | 11 | $258 |
| Neurocrine BioSciences, Inc. | 11 | $244 |
| Supernus Pharmaceuticals, Inc. | 13 | $203 |
| E.R. Squibb & Sons, L.L.C. | 9 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $198 |
| Teva Pharmaceuticals USA, Inc. | 6 | $122 |
| Vanda Pharmaceuticals Inc. | 4 | $105 |
Products named: ARISTADA, VRAYLAR, Auvelity, INGREZZA, INVEGA SUSTENNA, Qelbree, CAPLYTA, COBENFY.
Industry payments across CA — which companies pay providers there.
